newsfilter
← Latest News
Business Wire·

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

- $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization